The variability concerning access to advanced diagnostic tests such as biomarkers, which is more often recommended but not universally available, is also incredibly significant [ 7 , 8 ].
← all excerpts
Neurologists' approaches and challenges in managing early-stage Alzheimer's disease: A survey of clinical practices.
1
—
—